Pregabalin Capsule
Product Images NDC 60687-484

Product Visual Gallery

This gallery contains 29 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 60687-484). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ahp47301

Pregabalin 25 mg oral capsule with imprint code "LA 41" on a white, oblong capsule. The image shows both sides of the capsule. Labeler is American Health Packaging.*

FDA Label Image

Ahp48401

Pregabalin 50 mg oral capsule imprinted with "LA 42" on the white capsule body, shown from two angles. The capsule is white with no additional markings visible. Labeler is American Health Packaging.*

FDA Label Image

Ahp49501

Pregabalin 50 mg oral capsules with a red and white color scheme. The capsule displays the imprint 'LA 43' on the white half. Manufactured or labeled by American Health Packaging.*

FDA Label Image

Ahp50602

Pregabalin 100 mg oral capsule shown in a red, opaque capsule form. One side of the capsule is imprinted with the code 'LA 44'. The capsule is designed for human prescription use and labeled by American Health Packaging.*

FDA Label Image

Ahp51702

Pregabalin 45 mg white capsule with imprint 'LA 45'. The capsule is shown from two angles, displaying the imprint on one side and plain white on the other. Detailed strength of 45 mg is visible; the product is an oral capsule by American Health Packaging.*

FDA Label Image

Cockcroft And Gault-equation (Cockcroft And Gault Equation)

The image displays a formula for calculating creatinine clearance (CLCr), which includes variables for age in years, weight in kilograms, serum creatinine in mg/dL, and a factor for female patients. The formula is presented as a mathematical expression.*

FDA Label Image

Structural Formula (Structure)

Chemical structure of the active ingredient pregabalin, showing its molecular arrangement with amino and carboxyl functional groups.*

FDA Label Image

Figure 1: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Dpn 1 (Figure 1)

A line chart comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 200 mg, 100 mg, and 25 mg taken three times a day, as well as a placebo. The chart shows different curves representing each dosage and placebo across increasing pain improvement percentages.*

FDA Label Image

Figure 2: Patients Achieving Various Levels Of Improvement In Pain Intensity– Study Dpn 2 (Figure 2)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day and placebo. The graph shows two curves with Pregabalin demonstrating a higher percentage of patients improved across increasing pain improvement thresholds compared to placebo.*

FDA Label Image

Figure 3: Patients Achieving Various Levels Of Improvement In Pain Intensity– Study Phn 1 (Figure 3)

A line graph showing the percent of patients improved versus the percent improvement in pain from baseline, comparing Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken three times a day, against a placebo. The graph illustrates that higher doses of Pregabalin correspond with greater patient improvement.*

FDA Label Image

Figure 4: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Phn 2 (Figure 4)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows trends in pain improvement for each treatment group.*

FDA Label Image

Figure 5: Patients Achieving Various Levels Of Improvement In Pain Intensity– Study Phn 3 (Figure 5)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo in terms of patient pain improvement percentages.*

FDA Label Image

Figure 6: Responder Rate By Adjunctive Epilepsy Study (Figure 6)

A bar chart showing responder rates (%) in two studies labeled E1 and E3. The x-axis lists different dose groups and placebo, while the y-axis shows response percentages. The chart compares multiple doses of pregabalin (50 mg/day to 600 mg/day) versus placebo with response rates increasing with dose.*

FDA Label Image

Figure 7: Seizure Reduction By Dose (all Partial-onset Seizures) For Studies E1, E2, And E3 (Figure 7)

A line graph depicting seizure reduction as median percentage change from baseline versus dose (mg/day) of pregabalin. Four studies (E1 BID, E2 TID, E3 BID, E3 TID) are represented by distinct markers and lines showing increased seizure reduction with higher doses up to 600 mg/day. Significant p-values are indicated at data points.*

FDA Label Image

Figure 8: Responder Rate (greater Than Or Equal To 50% Reduction) (Figure 8.jpg.jpg)

A bar chart showing responder rates (%) on the vertical axis for three groups: Placebo (22.6%, N=93), 2.5 mg/kg/day dosage (29.1%, N=103), and 10 mg/kg/day dosage (40.6%, N=96). The chart compares the responder rates for different dosage groups including placebo.*

FDA Label Image

Figure 9: Patients Achieving Various Levels Of Improvement In Pain Intensity – Fibromyalgia Study F1 (Figure 9)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at daily doses of 300 mg, 450 mg, and 600 mg, compared to placebo. The graph includes vertical reference lines at 30% and 50% improvement thresholds.*

FDA Label Image

Figure 10: Time To Loss Of Therapeutic Response, Fibromyalgia Study F2 (kaplan-meier Analysis) (Figure 10)

A line chart comparing the estimated percentage of subjects without LTR over a period of 180 days for Pregabalin versus Placebo. The x-axis represents days, and the y-axis shows the estimated percentage without LTR. Pregabalin has a higher percentage of subjects without LTR throughout the period compared to Placebo.*

FDA Label Image

Figure 11: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Sci 1 (Figure 11)

A line graph comparing percent of subjects improved in two groups, Pregabalin and Placebo, over a range of percent improved from baseline to Week 12 BOCF. The x-axis represents percent improved, and the y-axis shows percent of subjects improved, with Pregabalin showing higher improvement percentages compared to Placebo across the range.*

FDA Label Image

Figure 12: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Sci 2 (Figure 12)

A line chart comparing the percent of subjects improved over time from baseline to week 16 for Pregabalin versus Placebo. The x-axis represents the percent improved from baseline to week 16, and the y-axis shows the percent of subjects improved. Two lines are shown: one solid line for Pregabalin and one dashed line for Placebo, indicating a higher improvement percentage with Pregabalin across the timeline.*

FDA Label Image

25 mg Pregabalin Capsules Carton (25 mg Pregabalin Capsules Carton)

Pregabalin 25 mg capsules packaging label displaying 100 capsules (10 x 10) for oral use. The label includes the National Drug Code (NDC) 60687-473-01 and states it is for prescription use only (Rx Only). It notes the requirement for pharmacists to dispense a Medication Guide with each patient.*

FDA Label Image

25 mg Pregabalin Capsule Blister (25 mg Pregabalin Capsule Blister)

Label sheet showing multiple identical labels for Pregabalin 25 mg capsules, manufactured by American Health Packaging. Each label includes the drug name, dosage strength, capsule form, a barcode, and spaces for expiry date and lot number. The labeler location is Columbus, Ohio.*

FDA Label Image

50 mg Pregabalin Capsules Carton (50 mg Pregabalin Capsules Carton)

Packaging label for Pregabalin capsules 50 mg by American Health Packaging. The label shows a count of 100 capsules in a 10 by 10 configuration. It includes the NDC number 60687-484-01, barcode, dispenser instructions, storage conditions between 15°C to 30°C, and a QR code for the medication guide and prescribing information.*

FDA Label Image

50 mg Pregabalin Capsule Blister (50 mg Pregabalin Capsule Blister)

Multiple identical label panels for Pregabalin 50 mg capsules from American Health Packaging. Each label includes the product name, dosage strength of 50 mg, dosage form as capsule, bar code, and placeholder text for expiration date and lot number. The labeler information states American Health Packaging, Columbus, Ohio 43217.*

FDA Label Image

75 mg Pregabalin Capsules Carton (75 mg Pregabalin Capsules Carton)

Packaging label for Pregabalin capsules, 75 mg strength, with 100 capsules (10 x 10) per container. The label features the product name, dosage form, and strength prominently, along with NDC 60687-495-01. The label indicates Rx only and includes instructions for pharmacists to dispense a medication guide with each patient. Distributed by American Health Packaging.*

FDA Label Image

75 mg Pregabalin Capsule Blister (75 mg Pregabalin Capsule Blister)

Multiple identical labels for Pregabalin 75 mg oral capsules from American Health Packaging. Each label includes the product name, dosage strength, dosage form, a barcode, and fields for expiration date and lot number. The labeler location is Columbus, Ohio.*

FDA Label Image

100 mg Pregabalin Capsules Carton (100 mg Pregabalin Capsules Carton)

Label for Pregabalin 100 mg capsules by American Health Packaging. The label displays the product name, dosage strength, capsule count (100 capsules including 10 blister packs of 10), and Rx Only status. It includes handling instructions for pharmacists, storage temperature guidelines, and warnings about package integrity. A QR code for medication guide and prescribing information is also shown.*

FDA Label Image

100 mg Pregabalin Capsule Blister (100 mg Pregabalin Capsule Blister)

Multiple small labels for Pregabalin 100 mg capsules by American Health Packaging. Each label includes the drug name, dosage strength, dosage form, a National Drug Code (NDC) barcode, and space for expiration date and lot number. Labels show the manufacturer's location in Columbus, Ohio.*

FDA Label Image

150 mg Pregabalin Capsules Carton (150 mg Pregabalin Capsules Carton)

Label for Pregabalin capsules, 150 mg strength, with 100 capsules per package (10 x 10 count). The label includes dosing information, storage instructions, and a QR code for medication guide and prescribing information. Distributed by American Health Packaging.*

FDA Label Image

150 mg Pregabalin Capsule Blister (150 mg Pregabalin Capsule Blister)

Sheet of multiple small labels for Pregabalin 150 mg capsules. Each label includes the product name, strength, dosage form, a barcode, space for expiration and lot numbers, and the American Health Packaging labeler information from Columbus, Ohio.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.